Researchers have developed a new drug that shows potential in laboratory studies against a rare type of acute leukemia, according to a recent study. Additional studies suggest the same compound could play a role in prostate cancer treatment as well.
The compound was developed in the labs of Jolanta Grembecka, PhD, and Tomasz Cierpicki, PhD, at the University of Michigan Comprehensive Cancer Center in Ann Arbor. They have been working for several years to identify a small-molecule inhibitor that would block the interaction between the protein menin and MLL fusion proteins that cause a rare type of acute leukemia.
So-called MLL fusion leukemia can occur in both adults and children. It represents up to 10% of acute leukemia in adults, and approximately 70% of acute leukemia in infants. Current treatments are not very effective, with just over one-third of patients surviving 5 years.
Protein-protein interactions such as the menin-MLL fusion protein interactions in leukemia are generally considered undruggable, meaning it can be particularly challenging to develop drugs that target those interactions. Despite the difficulty, Grembecka said that the MLL-menin interaction remained tempting.
“In many types of cancer, you see multiple interactions and mutations that trigger the cancer. The MLL-menin interaction is a good drug target because it’s the primary driver in this type of leukemia. By blocking this interaction, it’s very likely to stop the cancer,” said Grembecka, assistant professor of pathology at the University of Michigan Medical School.
In a study published in Cancer Cell (2015; doi:10.1016/j.ccell.2015.02.016), the researchers tested two compounds they developed, MI-463 and MI-503, in cell lines and in mice with MLL leukemia. They found the compounds blocked the MLL-menin interaction without harming normal blood cells. The compounds were delivered into the blood and metabolized at a good rate, both of which are key issues in developing new drugs.
The researchers had previously tested an earlier version of the compound, which showed promise. Here, they substantially improved the drug’s potency and many of its pharmacologic properties, making it more attractive for potential use in humans.
“Against all odds, we decided to explore finding a way to block the MLL-menin interaction with small molecules. From nothing, we have been able to identify and greatly improve a compound and show that it’s got valuable potential in blocking MLL fusion leukemia in animal models,” said Cierpicki, assistant professor of pathology at the U-M Medical School.
Meanwhile, prostate cancer researchers at U-M discovered that menin and MLL play a role in androgen receptor signaling, which is a key driver of prostate cancer. In a study published in Nature Medicine (2015;21:344-352), the researchers tested the same MLL-menin inhibitors against castration resistant prostate cancer cells and mice models.
“Our study suggests that this MLL-menin inhibitor might also have a potential role in a more common solid tumor, in this case prostate cancer,” said Arul M. Chinnaiyan, MD, PhD, director of the Michigan Center for Translational Pathology and the senior author on the Nature Medicine paper.
The compounds must be tested further in the laboratory before any clinical trials could be considered. No treatments or trials are currently available using an MLL-menin inhibitor.